Compare Liberty Global Ltd Class C (LBTYK) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Global Ltd Class C vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Liberty Global Ltd Class C trades at $8.03 (market cap $2.94B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Liberty Global Ltd Class C is far larger — about 3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Global Ltd Class C for 20 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LBTYK | MRVI | |
|---|---|---|
Market Cap | $2.94B | $972.90M |
Volume | 1,441,876 | 4,325,710 |
Sector | Media | Health |
52-Week High | $12.67 | $9.00 |
52-Week Low | $8.03 | $2.83 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | $9.60B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Liberty Global (LBTYK) trades at $8.41, showing minimal daily movement with a 0.24% gain. The stock faces bearish technical signals but maintains strong analyst support with 69% buy ratings and a $12.67 consensus target. Recent financials show mixed performance with negative net income margins (-62.14%) despite solid gross margins (67.17%), while strategic moves like the Ziggo Group spin-off and AI partnerships aim to unlock value by 2027.
The outlook remains cautiously optimistic given the significant upside to analyst targets and ongoing corporate restructuring. Key risks include persistent profitability challenges and execution risks around the Ziggo listing. The stock's deep value proposition (P/S 0.59, P/B 0.31) offers potential for patient investors despite near-term volatility.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
